2 false false false false false false false true false false true false false false false false false No description of principal activity 2023-01-03 Sage Accounts Production Advanced 2023 - FRS102_2023 xbrli:pure xbrli:shares iso4217:GBP 14568344 2023-01-03 2024-01-31 14568344 2024-01-31 14568344 2023-01-02 14568344 bus:Director1 2023-01-03 2024-01-31 14568344 bus:Director2 2023-01-03 2024-01-31 14568344 core:WithinOneYear 2024-01-31 14568344 core:ShareCapital 2024-01-31 14568344 core:RetainedEarningsAccumulatedLosses 2024-01-31 14568344 bus:SmallEntities 2023-01-03 2024-01-31 14568344 bus:AuditExemptWithAccountantsReport 2023-01-03 2024-01-31 14568344 bus:SmallCompaniesRegimeForAccounts 2023-01-03 2024-01-31 14568344 bus:PrivateLimitedCompanyLtd 2023-01-03 2024-01-31 14568344 bus:FullAccounts 2023-01-03 2024-01-31
COMPANY REGISTRATION NUMBER: 14568344
Xenos Bio Limited
Filleted Unaudited Financial Statements
31 January 2024
Xenos Bio Limited
Financial Statements
Period from 3 January 2023 to 31 January 2024
Contents
Page
Statement of financial position
1
Notes to the financial statements
2
Xenos Bio Limited
Statement of Financial Position
31 January 2024
31 Jan 24
Note
£
Current assets
Cash at bank and in hand
10
Creditors: amounts falling due within one year
5
13
----
Net current liabilities
3
----
Total assets less current liabilities
( 3)
----
Capital and reserves
Called up share capital
10
Profit and loss account
( 13)
----
Shareholders deficit
( 3)
----
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
For the period ending 31 January 2024 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements were approved by the board of directors and authorised for issue on 6 September 2024 , and are signed on behalf of the board by:
Dr M Kab Omir
Mr A J Sheppard
Director
Director
Company registration number: 14568344
Xenos Bio Limited
Notes to the Financial Statements
Period from 3 January 2023 to 31 January 2024
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 71-75 Shelton Street, London, WC2H 9JQ, England.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis. The financial statements are prepared in sterling, which is the functional currency of the entity.
Going concern
The accounts have been prepared on a going concern basis which relies upon the continuing support of the shareholders.
Income statement
The company is dormant as defined by section 1169 of the Companies Act 2006. The company incurred no significant transactions during the current period.
Judgements and key sources of estimation uncertainty
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Financial instruments
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account in other administrative expenses. Loans and borrowings and initially recognised at the transaction price including transaction costs. Subsequently, they are measured at amortised cost using the effective interest rate method, less impairment. If an arrangement constitutes a finance transaction it is measured at present value.
4. Employee numbers
The average number of persons employed by the company during the period amounted to 2 .
5. Creditors: amounts falling due within one year
31 Jan 24
£
Trade creditors
13
----